1. Home
  2. TVGN

as of 08-28-2026 2:17pm EST

$6.89
+$0.14
+2.07%
Stocks Finance Blank Checks Nasdaq

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Founded: 2020 Country:
United States
United States
Employees: N/A City: WARREN
Market Cap: 21.3M IPO Year: 2021
Target Price: N/A AVG Volume (30 days): 6.7K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.16 EPS Growth: -11442.86
52 Week Low/High: $0.14 - $12.03 Next Earning Date: 05-13-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -2.14 Index: N/A
Free Cash Flow: -12393016.0 FCF Growth: N/A

AI-Powered TVGN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Accuracy: 68.63%
68.63%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2024
Q1

Q1 2024 Earnings

8-K

Apr 26, 2024

0001493152-24-016060

Transcript text not available. View on SEC.gov →

Share on Social Networks: